HCA VS LLY Stock Comparison
Performance
HCA10/100
10/100
HCA returned 4.32% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
LLY100/100
100/100
LLY returned 68.15% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
HCA75/100
75/100
22 analysts offer 12-month price targets for HCA. Together, they have an average target of 265.95, the most optimistic target put HCA at 315 within 12-months and the most pessimistic has HCA at 200.
LLY68/100
68/100
22 analysts offer 12-month price targets for LLY. Together, they have an average target of 391, the most optimistic target put LLY at 673 within 12-months and the most pessimistic has LLY at 236.
Technicals
HCA50/100
50/100
HCA receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.
LLY57/100
57/100
LLY receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.
Earnings
HCA10/100
10/100
HCA has missed earnings 6 times in the last 20 quarters.
LLY10/100
10/100
LLY has missed earnings 7 times in the last 20 quarters.
Profit
HCA78/100
78/100
Out of the last 20 quarters, HCA has had 20 profitable quarters and has increased their profits year over year on 10 of them.
LLY66/100
66/100
Out of the last 20 quarters, LLY has had 19 profitable quarters and has increased their profits year over year on 6 of them.
Volatility
HCA49/100
49/100
HCA has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.
LLY53/100
53/100
LLY has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.
Dividend
HCA23/100
23/100
HCA's most recent dividend was $0.35 per share, based on a share price of $237.58. It was a payout ratio of 11.37% compared to their total earnings.
LLY100/100
100/100
LLY's most recent dividend was $0.57 per share, based on a share price of $588.54. It was a payout ratio of 50.90% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
HCA Healthcare, Inc. Summary
New York Stock Exchange / HCA
Healthcare
Medical - Care Facilities
HCA Healthcare, Inc., through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. It also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, the company operates psychiatric hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. As of December 31, 2021, it operated 182 hospitals, including 175 general and acute care hospitals, five psychiatric hospitals, and two rehabilitation hospitals; 125 freestanding surgery centers; and 21 freestanding endoscopy centers in 20 states and England. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
Eli Lilly & Co. Summary
New York Stock Exchange / LLY
Healthcare
Drug Manufacturers - General
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare HCA to other companies in the same or a similar industry.